NCT06917079 BBO-11818 in Adult Subjects With KRAS Mutant Cancer
| NCT ID | NCT06917079 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) |
| Condition | Non-Small Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 665 participants |
| Start Date | 2025-03-31 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 665 participants in total. It began in 2025-03-31 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Eligibility Criteria
Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation * Measurable disease by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Life expectancy \>24 weeks * Adequate organ function Exclusion Criteria: * Malignancy within the last 2 years as specified in the protocol * Untreated brain metastases Other inclusion/exclusion criteria are specified in the protocol.
Contact & Investigator
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
✉ tbbo11818-101ct.gov@bbotx.com📞 (650) 405-4770
Frequently Asked Questions
Who can join the NCT06917079 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06917079 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06917079 currently recruiting?
Yes, NCT06917079 is actively recruiting participants. Contact the research team at tbbo11818-101ct.gov@bbotx.com for enrollment information.
Where is the NCT06917079 trial being conducted?
This trial is being conducted at Los Angeles, United States, Sacramento, United States, San Diego, United States, San Francisco, United States and 11 additional locations.
Who is sponsoring the NCT06917079 clinical trial?
NCT06917079 is sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). The trial plans to enroll 665 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.